



#36855

DATE: JUNE 8, 2015

SUBJECT: INTREXON CORPORATION - DISTRIBUTION
OPTION SYMBOL: XON
NEW SYMBOL: XON1
FUTURES SYMBOLS: XON1C/XON1D
NEW SYMBOLS: XON2C/XON2D
DATE: 6/9/15
*****CORRECTION*****

CONTRACT ADJUSTMENT - OPTIONS

EFFECTIVE DATE: June 9, 2015

OPTION SYMBOL: XON changes to XON1

STRIKE PRICES: No Change

NUMBER OF CONTRACTS: No Change

MULTIPLIER: 100 (e.g., a premium of 1.50 yields \$150; a strike of 45 yields \$4,500)

NEW DELIVERABLE PER CONTRACT

- 1) 100 Intrexon Corporation (XON) Common Shares
- 2) 16 ZIOPHRAM Oncology, Inc. (ZIOP) Common Shares
- 3) Cash in lieu of 0.2203 fractional ZIOP shares

SETTLEMENT ALLOCATION:

XON: 95%
ZIOP: 5%

CUSIPS:

XON: 46122T102
ZIOP: 98973P101

THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

PRICING

Until the cash in lieu amount is determined, the underlying price for XON1 will be determined as follows:

$$XON1 = XON + 0.162203 (ZIOP)$$

DELAYED SETTLEMENT

The XON and ZIOP components of the XON1 deliverable will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash component of the XON1 deliverable until the cash in lieu amount is determined. Upon determination of the cash in lieu amount, OCC will require Put exercisers and Call assignees to deliver the appropriate cash amount.

CONTRACT ADJUSTMENT - FUTURES

EFFECTIVE DATE:	June 9, 2015
FUTURES SYMBOLS:	XON1C changes to XON2C XON1D changes to XON2D
SETTLEMENT PRICES:	No Change
NUMBER OF CONTRACTS:	No Change
MULTIPLIER:	100 (e.g., a premium of 1.50 yields \$150)
NEW DELIVERABLE PER CONTRACT	1) 100 Intrexon Corporation (XON) Common Shares 2) 16 ZIOPHRAM Oncology, Inc. (ZIOP) Common Shares 3) Cash in lieu of 0.2203 fractional ZIOP shares
SETTLEMENT ALLOCATION:	XON: 95% ZIOP: 5%
CUSIPS:	XON: 46122T102 ZIOP: 98973P101

THE SETTLEMENT ALLOCATION IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION (NSCC), AND IS NOT INTENDED TO BE USED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS.

PRICING

The underlying price for the XON2C/XON2D Futures contract deliverables, expressed in term of current market value, would be calculated as follows:

$$\text{XON2D} = \text{XON} + 0.162203 (\text{ZIOP})$$

Please note that the valuation would apply only to the XON2C/XON2D deliverables in terms of current market value of the deliverable securities. The resulting price would not be equivalent to the daily settlement price of a futures contract month, whose determination would include cost of money carrying charges, adjustment for dividends, and other factors.

DELAYED SETTLEMENT

The XON and ZIOP components of the XON2C/XON2D deliverables will settle through National Securities Clearing Corporation (NSCC). OCC will delay settlement of the cash component of the XON2C/XON2D deliverables until the cash in lieu amount is determined. Upon determination of the cash in lieu amount, OCC will require delivery of the appropriate number of the cash amount.

BACKGROUND

Intrexon Corporation (XON) has announced a distribution of ZIOPHARM Oncology, Inc. (ZIOP) Common Shares. The distribution ratio is 0.162203 of a ZIOP share for each XON share held. The record date is June 4, 2015; the payable date is June 12, 2015. The New York Stock Exchange (NYSE) has set June 9, 2015, as the ex-distribution date for this distribution

ZIOPHARM Oncology, Inc. Common Shares are listed on the NASDAQ Stock Market under the trading symbol "ZIOP".

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.